A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
Status:
Completed
Trial end date:
2010-08-18
Target enrollment:
Participant gender:
Summary
This clinical study is being conducted at multiple sites to determine the best confirmed
response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell
carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic
forms; subjects with either classification will be accepted into this study.